Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults

NCT05384041 | Completed Results FDA Device

• 1 other identifier: FW-200-05
• Study Type: interventional
• Target: 255
• Locations: 1 country
• Sites: 1

Brief Summary

This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in adults.

Conditions

Major Depressive Disorder

Keywords

MDD; Depression; Depressive Disorder; Major Depressive Disorder; Cranial Electrotherapy Stimulation; FW-200

Outcome Measures

Primary Outcomes (1)

• Change in the Beck Depression Inventory Second Edition (BDI-II) at Week Two Compared to Baseline.

  The Beck Depression Inventory Second Edition (BDI-II) is a multiple-choice self-report inventory that assesses severity of depression. The BDI-II contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). The minimum score is 0 and the maximum score is 63, with a higher score indicating more severe depressive symptoms. The candidate subject's BDI-II score must be within the range of 20 to 63 indicating moderate to severe Major Depressive Disorder.

  Change at week two compared to baseline.

Secondary Outcomes (4)

• Change in the Beck Depression Inventory Second Edition (BDI-II) at Weeks One and Four Compared to Baseline.

  Change at weeks one and four compared to baseline.

• Change in the Patient Health Questionnaire-9 (PHQ-9) at Weeks One, Two, and Four Compared to Baseline.

  Change at weeks one, two, and four compared to baseline.

• Change in the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) at Weeks One, Two, and Four Compared to Baseline.

  Change at weeks one, two, and four compared to baseline.

• Beck Depression Inventory Second Edition (BDI-II) Responder Rate by Time Point (% of Subjects With a 50% or Better Improvement in Score From Baseline).

  Four weeks following baseline.

Study Arms (2)

Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)

ACTIVE COMPARATOR

The Fisher Wallace Stimulator provides cranial electrotherapy stimulation and is an active device.

Device: Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)

Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)

PLACEBO COMPARATOR

The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.

Device: Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)

Interventions

Fisher Wallace Cranial Electrotherapy Stimulator (Active Device) DEVICE

The indicated use in adults (ages 21-65 years) is for 20 minutes twice daily, upon waking for the day and at bedtime. The treatment period of the intervention will have a duration of four weeks.

Also known as: Fisher Wallace Stimulator FW-200, FW-200

Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)

Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device) DEVICE

The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.

Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 21-65 years and a resident of the United States of America
• Meets DSM-5 diagnostic criteria for moderate to severe Major Depressive Disorder
• Baseline BDI-II score between 20 and 63, inclusive (in moderate to severe range)
• Able to receive packages to their home via United Parcel Service/Fedex/United States Postal Service or other delivery service
• Willing and able to send and receive study related text messages on an internet capable mobile device throughout the duration of the study
• Owns and uses a personal, verifiable email address
• Able to commit to two (2) 20-minute treatment sessions per day for 4 weeks, one treatment upon waking for the day and one treatment before going to bed
• Willing to abstain from use of recreational drugs, hypnotics, steroids, and/or marijuana products through study completion
• Willingness to not initiate treatment for a mental health issue during the course of the study
• Fluent in English
• Sexually active females of childbearing potential willing to commit to practicing at least one or more of the following methods of contraception during the study: intrauterine device (IUD), barrier method in combination with a spermicide, oral/hormonal contraception, or abstinence
• In the opinion of the investigator, able to comply with study requirements and complete the study

You may not qualify if:

• History of suicide attempt or active suicidal ideation with plan or intent in the past 30 days.
• In the opinion of the investigator, considered high risk of suicide
• Previous hospitalization or institutionalization for mental health condition within one year of study entry
• Underwent electronic brain stimulation or neuromodulation within the past one year, including CES, transcranial magnetic stimulation, electroconvulsive therapy, and deep brain stimulation
• Modification of prescription medications that affect the nervous system (e.g., psychotropic medications) within 30 days of study entry
• Use of recreational drugs, hypnotics, steroids, and/or marijuana products in the past 30 days
• History of alcohol use disorder or other substance use disorder in the past 12 months
• Females currently pregnant or planning to conceive during study participation, or unwilling to comply with birth control requirements
• Known history of heart disease
• Known history of trigeminal neuralgia
• Implanted with an electronic device such as a defibrillator, deep brain stimulator, or pacemaker
• Unstable medical condition including any condition requiring hospitalization or change in treatment in the prior 30 days
• Legally blind and/or deaf and without in-home care service to assist with study participation
• Meets M.I.N.I. assessment criteria for, or has been diagnosed with, any of the following: Bipolar I disorder, bipolar II disorder, other specified bipolar and related disorder, panic disorder, agoraphobia, social anxiety disorder (social phobia), obsessive-compulsive disorder, posttraumatic stress disorder, alcohol use disorder in the past 12 months, substance use disorder (non-alcohol) in the past 12 months, any psychotic disorder (e.g., schizophrenia, schizoaffective disorder), major depressive disorder with psychotic features, anorexia nervosa, bulimia nervosa, binge-eating disorder, generalized anxiety disorder, any cognitive or developmental disorder (e.g., autism, Down's Syndrome), any personality disorder or psychiatric disorder that may interfere with study participation
• Current participation in another investigational study or participated in an investigational study within the past 30 days

Sponsors & Collaborators

• Fisher Wallace Laboratories: lead
• NAMSA: collaborator
• Climb Technologies, Inc.: collaborator

Study Sites (1)

New York Neuromodulation Medical, PLLC

New York, New York, 10023, United States

Location

Related Publications (1)

• Gehrman PR, Bartky EJ, Travers C, Lapidus K. A Fully Remote Randomized Trial of Transcranial Alternating Current Stimulation for the Acute Treatment of Major Depressive Disorder. J Clin Psychiatry. 2024 Apr 22;85(2):23m15078. doi: 10.4088/JCP.23m15078.

  PMID: 38696220 DERIVED

MeSH Terms

Conditions

Depressive Disorder, Major; Depression; Depressive Disorder

Condition Hierarchy (Ancestors)

Mood Disorders; Mental Disorders; Behavioral Symptoms; Behavior

Results Point of Contact

• Title: Julia Lanoha
• Organization: Climb Technologies, Inc.

julia@climb.care

(925) 405-5458

Study Officials

• Kyle Lapidus, MD, PhD

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Remote, randomized, decentralized, controlled, triple-blind (subject, Principal Investigator, Sponsor) pivotal investigation.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Pivotal Study

Study Record Dates

• First Submitted: May 12, 2022
• First Posted: May 20, 2022
• Study Start: April 28, 2022
• Primary Completion: September 30, 2022
• Study Completion: October 24, 2022
• Last Updated: March 12, 2024
• Results First Posted: May 25, 2023

Record last verified: 2024-02

Locations

US (1)